<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arnold S Freedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jon C Aster, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Lister, MD, FRCP, FRCPath, FRCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The peripheral T cell lymphomas (PTCL) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHL) in adults [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">
          "Classification of hematopoietic neoplasms"
         </a>
         .)
        </p>
        <p>
         Among these, in decreasing frequency of occurrence, are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral T cell lymphoma, not otherwise specified (NOS)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anaplastic large cell lymphoma, primary systemic type
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angioimmunoblastic T cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extranodal NK/T cell lymphoma, nasal type (ENKL)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subcutaneous panniculitis-like T cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteropathy associated T cell lymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatosplenic T cell lymphoma
        </p>
        <p>
        </p>
        <p>
         Extranodal natural killer/T cell lymphoma, nasal type (ENKL), or nasal NK/T cell lymphoma (formerly called angiocentric lymphoma) most commonly presents in the nasopharynx, but may also involve other extranodal sites. The tumor cells are latently infected with Epstein-Barr virus (EBV) and most cases have a natural killer (NK) cell phenotype.
        </p>
        <p>
         The clinical presentation, pathologic features, and diagnosis of ENKL will be discussed here. The treatment and prognosis of ENKL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/16591.html" rel="external">
          "Treatment of extranodal NK/T cell lymphoma, nasal type"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nasal-type NK/T cell lymphoma is most common in Asia (eg, China, Japan, Korea, Hong Kong) and in native populations of Central and South America (eg, Peru and Mexico) where it accounts for 5 to 10 percent of all non-Hodgkin lymphoma [
         <a href="#rid3">
          3-11
         </a>
         ]. It is a rare disorder in the United States, Europe, South Asia, the Middle East, and Africa. In the United States, the incidence is highest among Hispanic White Americans and Asian/Pacific Islanders and lowest among Black Americans, non-Hispanic White Americans, and American Indian/Alaska natives [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The median age at presentation is 52 years [
         <a href="#rid8">
          8
         </a>
         ]; however, rare cases have been reported in childhood. There is a male predominance of approximately 2:1 [
         <a href="#rid5">
          5,8,13,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of ENKL is poorly understood but is related in part to infection of the tumor cells with Epstein-Barr virus (EBV). In virtually all cases, the tumor cells contain monoclonal episomal EBV genomes and express EBV-encoded small nuclear RNAs (EBERs). Expression of EBV latent membrane protein-1 (LMP-1) by immunohistochemistry has also been described [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          p53 overexpression
         </strong>
         – A high percentage of these tumors overexpress the p53 tumor suppressor protein, which is due to
         <em>
          TP53
         </em>
         mutation in a substantial minority of tumors [
         <a href="#rid16">
          16-18
         </a>
         ]. Curiously, the cyclin dependent kinase inhibitor p21, which is a downstream target of p53, is overexpressed in these tumors independent of
         <em>
          TP53
         </em>
         mutational status [
         <a href="#rid16">
          16
         </a>
         ]. In most other tumor types, p21 overexpression is linked to wild-type p53 expression, but in this tumor it has been found even with mutant p53 or low p53 expression; it is hypothesized that p21 overexpression may be related to EBV infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other mutations
         </strong>
         – Other frequently mutated genes include those encoding components of the JAK/STAT pathway, particularly
         <em>
          JAK3
         </em>
         [
         <a href="#rid19">
          19,20
         </a>
         ], suggesting that increased JAK/STAT signaling contributes to the growth and survival of ENKL cells. Mutations in genes encoding RNA helicases (particularly
         <em>
          DDX3
         </em>
         ) and epigenetic regulators have been reported [
         <a href="#rid21">
          21
         </a>
         ]. Other tumor suppressor genes that have been implicated in the pathogenesis of ENKL include
         <em>
          PRDM1
         </em>
         (also known as Blimp-1), which lies within a region on chromosome 6 that is frequently deleted in ENKL [
         <a href="#rid22">
          22
         </a>
         ], and
         <em>
          FOXO3
         </em>
         . One study reported that most tumors had down-regulated
         <em>
          PRDM1
         </em>
         and
         <em>
          FOXO3
         </em>
         , in association with nonsense and missense mutations [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epigenetic effects
         </strong>
         – The
         <em>
          TP73
         </em>
         gene, which shares structural and functional homology with
         <em>
          TP53
         </em>
         and is thought to be a tumor suppressor gene, has been found to be highly methylated in these tumors; less often, the genes that encode the tumor suppressors, p16 (cyclin-dependent kinase inhibitor 2A [CDKN2A]) and p15 (cyclin dependent kinase inhibitor 2B [
         <em>
          CDKN2B
         </em>
         ]) are hypermethylated [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The large majority of patients present with localized disease resulting in symptoms of nasal obstruction, epistaxis, and/or a destructive mass involving the nose, sinuses, or palate  (
         <a class="graphic graphic_diagnosticimage graphicRef72858" href="/z/d/graphic/72858.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid5">
          5,13,25,26
         </a>
         ]. Other extranodal sites may be involved either primarily (ie, extranasal NK/T cell lymphoma) or as a direct extension of the primary tumor. These sites include the upper airway, Waldeyer's ring, gastrointestinal tract, skin, testis, lung, eye, or soft tissue [
         <a href="#rid8">
          8,26-35
         </a>
         ]. Lymph nodes may be involved secondarily, but are only rarely the primary site of involvement [
         <a href="#rid28">
          28
         </a>
         ]. Bone marrow involvement and B symptoms (ie, fever, night sweats, weight loss) are seen in approximately 10 and 35 percent of patients, respectively [
         <a href="#rid8">
          8,14
         </a>
         ].
        </p>
        <p>
         As an example, a retrospective analysis of 145 patients with nasal-type NK/T cell lymphoma reported that the majority of patients presented with Ann Arbor stage I (81 percent) or II (17 percent) disease, with nodal involvement being uncommon (17 percent). Systemic B symptoms or an elevated lactate dehydrogenase level were seen in 34 and 46 percent of patients, respectively [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Another single institution analysis compared the presentation and clinical outcomes of nasal (181 patients) and extranasal (50 patients) ENKL [
         <a href="#rid26">
          26
         </a>
         ]. When compared with nasal NK/T cell lymphoma, extranasal NK/T cell lymphoma had a slightly different immunophenotype and was more likely to present with stage II or greater disease (56 versus 20 percent), B symptoms (54 versus 37 percent), and impaired performance status (10 versus 3 percent). However, the outcomes were similar for nasal and extranasal NK/T cell lymphoma when matched for stage.
        </p>
        <p>
         Importantly, approximately 3 percent of ENKL are associated with the hemophagocytic syndrome, an often fatal complication, which may present with high fevers, maculopapular rash, failure to thrive, central nervous system symptoms, hepatosplenomegaly, lymphadenopathy, cytopenias, coagulopathy, abnormal liver function tests, or extremely high serum ferritin levels [
         <a href="#rid8">
          8,36-38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8384.html" rel="external">
          "Treatment and prognosis of hemophagocytic lymphohistiocytosis"
         </a>
         .)
        </p>
        <p>
         Some cases of the aggressive variant of NK cell leukemia/lymphoma may be related to and seen in conjunction with ENKL [
         <a href="#rid39">
          39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4538.html" rel="external">
          "Natural killer (NK) cell large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          PATHOLOGIC FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Morphologic features
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Growth pattern
         </span>
         <span class="headingEndMark">
          —
         </span>
         Involved tissues usually demonstrate extensive ulceration and a diffuse, permeative lymphomatous infiltrate. Mucosal glands, if present, are widely spaced and there is usually prominent coagulative necrosis of both tumor cells and normal tissue [
         <a href="#rid1">
          1
         </a>
         ]. An angiocentric/angiodestructive growth pattern is a characteristic, but not essential, feature that is associated with fibrinoid necrosis of blood vessel walls. Vascular lumina may be occluded by lymphoid cells with varying degrees of cytologic atypia [
         <a href="#rid40">
          40
         </a>
         ], sometimes in association with thrombosis. Mitotic figures are variably plentiful, but usually common.
        </p>
        <p>
         The polymorphous infiltrate is composed of a mixture of normal-appearing small lymphocytes and atypical lymphoid cells of varying size [
         <a href="#rid28">
          28,29
         </a>
         ], along with plasma cells and occasionally eosinophils and macrophages  (
         <a class="graphic graphic_picture graphicRef59281" href="/z/d/graphic/59281.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Cell morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         The morphology of the tumor cells in ENKL varies widely. The cells can be of any size, but most commonly are either medium-sized or a mixture of small and large cells. They often have a moderate amount of pale/clear cytoplasm, irregularly folded nuclei, granular chromatin, and inconspicuous or small nucleoli [
         <a href="#rid1">
          1
         </a>
         ]. Azurophilic granules may be seen on touch preps stained with Giemsa.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Immunophenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         The immunophenotype of ENKL is usually similar to that of a natural killer (NK) cell. The atypical cells in most cases express CD2, CD56, and cytoplasmic CD3, but do not express surface CD3. Most cases express cytotoxic granule proteins such as granzyme B, TIA-1, and perforin, and lack surface T cell receptor (TCR) [
         <a href="#rid15">
          15,41
         </a>
         ]. Uncommon cases may express CD4, CD8, and/or CD7 [
         <a href="#rid29">
          29,30,42
         </a>
         ]. The tumor cells may also express CD30, particularly in cases in which large cells predominate, potentially leading to misdiagnosis as anaplastic large cell lymphoma [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Genetic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          TCR
         </em>
         and immunoglobulin (
         <em>
          Ig
         </em>
         ) genes are usually germline, but a minor fraction of cases demonstrate clonal rearrangement of
         <em>
          TCR
         </em>
         genes, suggesting derivation from a cytotoxic T lymphocyte [
         <a href="#rid33">
          33
         </a>
         ]. Clonal Epstein-Barr virus (EBV) genomes are virtually always present [
         <a href="#rid30">
          30,31,44
         </a>
         ]. In situ hybridization for EBV encoded small nuclear RNAs (EBERs) is the preferred method of demonstrating the presence of EBV.
        </p>
        <p>
         Many genetic abnormalities have been reported, but there is no typical or diagnostic cytogenetic change. The most common cytogenetic abnormality is deletion of chromosome 6q [
         <a href="#rid22">
          22,45
         </a>
         ]. As mentioned above,
         <em>
          PRDM1
         </em>
         is one candidate tumor suppressor gene that maps to the deleted region. Genome-wide association studies (GWAS) have implicated single-nucleotide polymorphisms (SNPs) of certain human leukocyte antigen (HLA) genes and
         <em>
          IL18RAP
         </em>
         in the genetic risk for NKTCL development [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of ENKL is made based on the evaluation of a biopsy specimen from the site of involvement, usually in the midfacial area  (
         <a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">
          table 1
         </a>
         ). Because the morphology of the tumor cells is so variable, it is important to consider this diagnosis in all cases of aggressive extranodal lymphoma, including unusual cases presenting outside of the nasopharynx, particularly when vascular invasion and necrosis are noted. Given the aggressive nature of these tumors the evaluation of suspected cases should be carried out with a sense of urgency, usually with a biopsy performed within one week.
        </p>
        <p>
         The key diagnostic features are the demonstration of natural killer (NK)/T cell markers and Epstein-Barr virus (EBV). Although CD56 is typically expressed, tumors that do not express CD56 may still be classified as ENKL if both cytotoxic molecules and EBV are positive [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         As described above, the histology is typically characterized by a polymorphous lymphoid infiltrate that invades the vascular walls, producing fibrinoid necrosis of vessel walls and coagulative necrosis of surrounding tissues. The tumor cells are highly variable in morphology; sometimes small or large cells predominate, but most often there is a mixture of small and large cells. (See
         <a class="local">
          'Morphologic features'
         </a>
         above.)
        </p>
        <p>
         Over 90 percent of cases are of true NK cell origin. These tumors express CD2, cytoplasmic CD3, CD56, and cytotoxic granule proteins, are negative for surface CD3, and have T cell receptor genes in the germline configuration. (See
         <a class="local">
          'Immunophenotype'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of ENKL includes other natural killer (NK) and T cell hematologic malignancies and Epstein-Barr virus (EBV)-associated T cell or NK cell lymphoproliferative disorders, certain subsets of which occur predominately in children (eg, chronic active EBV infection, systemic EBV-positive T cell lymphoma of childhood and hydroa vacciniforme-like lymphoproliferative disorder [
         <a href="#rid2">
          2,48
         </a>
         ]). (See
         <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">
          "Infectious mononucleosis", section on 'Chronic active EBV infection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          NK cell leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infrequently, patients with ENKL can have involvement of the bone marrow and peripheral blood resembling that seen in aggressive NK cell leukemia. It is unclear whether these are two distinct pathologic entities or if they merely represent two different clinical presentations (ie, leukemia and lymphoma) of a single entity.
        </p>
        <p>
         The immunophenotype of aggressive NK cell leukemia is practically identical to that of ENKL. In addition, EBV involvement is common in both entities. However, aggressive NK cell leukemia frequently expresses CD16 (75 percent of cases), while CD16 is typically negative in ENKL [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Lymphomatoid granulomatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphomatoid granulomatosis is another EBV-positive tumor that appears at extranodal sites and can bear a close histologic resemblance to ENKL. Cases of pulmonary "lymphomatoid granulomatosis" were for a time considered to be part of the spectrum of ENKL. However, the EBV-positive tumor cells in lymphomatoid granulomatosis are of B cell origin and thus express pan-B cell markers such as CD20, while the EBV-positive cells in ENKL are of NK or T cell origin. (See
         <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">
          "Pulmonary lymphomatoid granulomatosis", section on 'Pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3484176419">
         <span class="h2">
          EBV-positive mucocutaneous ulcer
         </span>
         <span class="headingEndMark">
          —
         </span>
         EBV-positive mucocutaneous ulcers are defined by the presence of isolated circumscribed ulcerative lesions, typically occurring in elderly individuals, sometimes in the setting of immunosuppression [
         <a href="#rid49">
          49
         </a>
         ]. The lesions are most common in the oropharynx, but may also occur in the skin or in the gastrointestinal tract. The lesions contain a polymorphous inflammatory infiltrate mixed with scattered EBV-infected B cells, which frequently include cells resembling Hodgkin/Reed-Sternberg cells morphologically and immunophenotypically. The entity is distinguished from Hodgkin lymphoma by its extranodal presentation and benign course, including frequent spontaneous regressions and excellent responses to conservative treatments.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          EBV-positive diffuse large B cell lymphoma, NOS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EBV-positive diffuse large B cell lymphoma (DLBCL), not otherwise specified, is a variant of DLBCL that often presents at extranodal sites and may exhibit angioinvasion, angiodestruction, and extensive tissue necrosis. However, unlike ENKL, presentations in the nasopharynx are unusual, the tumor cells are positive for B cell markers (CD20, CD79a), and genotypic studies reveal the presence of clonal immunoglobulin rearrangements. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Peripheral T cell lymphoma, unspecified
         </span>
         <span class="headingEndMark">
          —
         </span>
         T cell lymphomas that cannot be classified into a specific subtype, are labeled peripheral T cell lymphoma, unspecified. Tumors that express CD3 but do not express CD56 and are negative for EBV and cytotoxic molecules should be diagnosed as peripheral T cell lymphoma, unspecified rather than ENKL. Node-based EBV-positive PTCL are also classified as peripheral T cell lymphoma, unspecified [
         <a href="#rid2">
          2
         </a>
         ]. These monomorphic tumors often present in older adults and lack the angioinvasion and necrosis typical of ENKL. (See
         <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3533280750">
         <span class="h2">
          Anaplastic large cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some ENKL tumors are diffusely positive for CD30, and particularly in instances where large cells predominate, such tumors may be misdiagnosed as anaplastic large cell lymphoma (ALCL), ALK-negative. The distinction from ALCL can be made by performing tests for EBV, which is never present in ALCL and virtually always present in ENKL. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Hepatosplenic T cell lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hepatosplenic T cell lymphoma is a neoplasm of mature gamma/delta T cells that infiltrate the sinusoids of the spleen, liver, and bone marrow. The immunophenotype may resemble that seen in ENKL with expression of CD2, CD7, and variable expression of CD56. However, these tumors also express surface CD3 and surface T cell receptors (usually of the gamma/delta type), findings atypical for ENKL. In addition, these tumors do not typically express granzyme B or perforin, which are found in extranodal NK/T cell lymphoma. Isochromosome 7, a genetic aberration that is not seen in ENKL, is present in most cases. (See
         <a class="medical medical_review" href="/z/d/html/4714.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Squamous cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some cases of ENKL may elicit prominent pseudoepitheliomatous hyperplasia of the overlying mucosal epithelium that can resemble squamous cell carcinoma. While exuberant, the epithelial hyperplasia lacks atypia, whereas the underlying lymphoid infiltrate is usually overtly malignant. Detection of EBV in the lymphoid tumor cells is a helpful finding in unusual cases of ENKL that are comprised mainly of small lymphoid cells and that lack areas of necrosis. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Nonkeratinizing nasopharyngeal carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonkeratinizing nasopharyngeal carcinoma (NPC) is an epithelial neoplasm arising from the epithelial lining of the nasopharynx that has a similar clinical presentation to ENKL. In addition, both pathologic entities are associated with EBV infection.
        </p>
        <p>
         Nonkeratinizing NPCs are characterized by a dense lymphoplasmacellular infiltrate containing cohesive nests or scattered tumor cells  (
         <a class="graphic graphic_picture graphicRef73439" href="/z/d/graphic/73439.html" rel="external">
          picture 2
         </a>
         ). The neoplastic cells have large nuclei, prominent eosinophilic nucleoli, and scant cytoplasm. When growing in clusters, the cell borders are indistinct, thus giving a syncytial appearance. The tumor sometimes contains numerous infiltrating lymphocytes, primarily T cells, but these cells are morphologically benign. NPC can be distinguished from ENKL by performing immunohistochemical stains for cytokeratin, which are positive in NPC and negative in ENKL. (See
         <a class="medical medical_review" href="/z/d/html/3375.html" rel="external">
          "Pathology of head and neck neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H185382651">
         <span class="h2">
          NK cell enteropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         NK cell enteropathy is a proposed clinicopathologic entity characterized by involvement of the gastrointestinal mucosa by an extensive atypical NK cell lymphoproliferative process with an indolent course [
         <a href="#rid50">
          50,51
         </a>
         ]. Gastrointestinal biopsy reveals expansion of the lamina propria by a well-circumscribed but confluent infiltrate. The tumor is comprised of intermediate-sized cells with irregular nuclei, inconspicuous nucleoli, finely clumped chromatin, and a moderate amount of pale cytoplasm. There can be sheets of atypical cells with destruction of the mucosal glands, but necrosis is otherwise absent. There is no epitheliotropism, angiocentricity or angiodestructive growth, and NK cell enteropathy is not EBV-associated. The atypical cells characteristically express CD7, cytoplasmic CD3, TIA-1 and/or Granzyme B, but not CD4, CD5, CD8, CD10, CD20, CD30, PAX-5, CD138, or CD68. The MIB-1/Ki-67 proliferation fraction is low. T cell receptor studies are oligoclonal or polyclonal. The peripheral blood and bone marrow are not involved.
        </p>
        <p>
         Tumors involving the gastrointestinal tract with EBV positivity and/or a high proliferation fraction are better considered variants of aggressive ENKL than NK cell enteropathy [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1191956933">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">
          "Society guideline links: Lymphoma diagnosis and staging"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Extranodal natural killer (NK)/T cell lymphoma, nasal-type (ENKL)
         </strong>
         is an extranodal lymphoma most common in Asia and Central and South America, which typically presents with localized disease resulting in symptoms of nasal obstruction, epistaxis, and/or a destructive mass involving the nose, sinuses, or palate  (
         <a class="graphic graphic_diagnosticimage graphicRef72858" href="/z/d/graphic/72858.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         is made based on the evaluation of a biopsy specimen from the site of involvement  (
         <a class="graphic graphic_table graphicRef55385" href="/z/d/graphic/55385.html" rel="external">
          table 1
         </a>
         ). The histology is typically characterized by a polymorphous lymphoid infiltrate with highly variable morphology that invades the vascular walls, often producing extensive necrosis. The key diagnostic features are the demonstration of NK/T cell markers on immunophenotyping (typically CD2+, CD56, cytoplasmic CD3+, surface CD3–, CD4+/-, and CD8+/-) and the presence of Epstein-Barr virus (EBV), usually by in situ hybridization for EBV-encoded RNA (EBER). (See
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Pathologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         includes other NK and T cell hematologic malignancies and EBV-associated T cell or NK cell lymphoproliferative disorders. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Weiss LM, Albújar PF, et al. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol 1993; 17:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrionuevo C, Zaharia M, Martinez MT, et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007; 15:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009; 147:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113:3931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au WY, Ma SY, Chim CS, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014; 164:536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams SV, Newcomb PA, Shustov AR. Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States. J Clin Oncol 2016; 34:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009; 15:2905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanavaros P, Lescs MC, Brière J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993; 81:2688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintanilla-Martinez L, Kremer M, Keller G, et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. Am J Pathol 2001; 159:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol 1999; 30:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000; 80:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo GC, Tan SY, Tang T, et al. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2012; 2:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchekioua A, Scourzic L, de Wever O, et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014; 28:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiong J, Cui BW, Wang N, et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell 2020; 37:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun HS, Su IJ, Lin YC, et al. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol 2003; 122:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karube K, Nakagawa M, Tsuzuki S, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses. Blood 2011; 118:3195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu LL, Chan JK, Wong KF, Kwong YL. Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved. Am J Pathol 2002; 160:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu QF, Wang WH, Wang SL, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma. Int J Radiat Oncol Biol Phys 2014; 88:806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li YX, Fang H, Liu QF, et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112:3057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89:4501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JK, Ng CS, Lau WH, Lo ST. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987; 11:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol 1991; 15:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lei KI, Chan LY, Chan WY, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002; 8:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type. Hematol Oncol 1990; 8:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipford EH Jr, Margolick JB, Longo DL, et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 1988; 72:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chim CS, Au WY, Shek TW, et al. Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer 2001; 91:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lan SK, Lin CW, Ho HC, et al. Penile metastasis secondary to nasal NK/T-cell lymphoma. Urology 2008; 72:1014.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falini B, Pileri S, De Solas I, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood 1990; 75:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okuda T, Sakamoto S, Deguchi T, et al. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia. Am J Hematol 1991; 38:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han L, Li L, Wu J, et al. Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome. Leuk Lymphoma 2014; 55:2048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soler J, Bordes R, Ortũno F, et al. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol 1994; 86:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol 1998; 11:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990; 21:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawamoto K, Miyoshi H, Suzuki T, et al. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy. Hematol Oncol 2018; 36:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JK, Yip TT, Tsang WY, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994; 18:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol 2000; 157:1803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. Lancet Oncol 2020; 21:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li Z, Xia Y, Feng LN, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncol 2016; 17:1240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintanilla-Martinez L, Ridaura C, Nagl F, et al. Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood 2013; 122:3101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol 2010; 34:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011; 117:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takeuchi K, Yokoyama M, Ishizawa S, et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010; 116:5631.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4712 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26980727" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8540601" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8388175" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14716773" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17536305" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19604234" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19029440" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15668271" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23086753" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24245986" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Differences in incidence and trends of haematological malignancies in Japan and the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962200" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933580" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19318493" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8387835" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11733360" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10414505" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10780666" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mutations of the p53 gene in nasal NK/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22705984" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23689514" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32183952" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12899714" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21690554" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11786399" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576916" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24495590" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18676879" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192774" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3496014" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1996731" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11801537" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1979042" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Presence of Epstein-Barr virus DNA in nasal lymphomas of B and 'T' cell type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3263153" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11169934" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Primary CD56 positive lymphomas of the gastrointestinal tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18639328" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Penile metastasis secondary to nasal NK/T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2153036" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Peripheral T-cell lymphoma associated with hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1746541" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hemophagocytic syndrome associated with aggressive natural killer cell leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359240" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8043452" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8608206" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Classification of natural killer (NK) cell and NK-like T-cell malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9720504" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2210727" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29052238" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067515" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106552" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Consistent patterns of allelic loss in natural killer cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31879220" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27470079" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23982171" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Hydroa vacciniforme-like lymphoma: a chronic EBV+ lymphoproliferative disorder with risk to develop a systemic lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20154586" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20966166" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20829373" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
